TYROBP 是透明细胞肾细胞癌的潜在预后生物标志物,FEBS Open Bio

当前位置： X-MOL 学术 › FEBS Open Bio › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

TYROBP 是透明细胞肾细胞癌的潜在预后生物标志物
FEBS Open Bio ( IF 2.8 ) Pub Date : 2020-10-04 , DOI: 10.1002/2211-5463.12993
Ping Wu ₁ , Tingting Xiang ₂ , Jing Wang ₃ , Run Lv ₄ , Guangzhen Wu ₅

Affiliation

透明细胞肾细胞癌 (ccRCC) 具有很高的复发率和转移率。尽管靶向治疗显着改善了一些 ccRCC 患者的预后，但中位生存率仍然很差。因此，仍然需要鉴定用于诊断和治疗的新的潜在靶标。在这里，我们通过分析癌症基因组图谱数据库筛选了 ccRCC 和正常组织之间差异表达的基因。我们确定了与不良预后相关的 55 个上调基因和 67 个下调基因。基因本体论和京都基因与基因组百科全书通路分析表明，这些基因与糖代谢过程、补体和凝血级联反应相关。此外，8 个下调基因（HRG、FABP1、ALDOB、PCK1、HAO2、CASR、PLG和HMGCS2）和两个上调基因（SERPINE1和TYROBP）被过滤掉。最后通过对各种数据库的反复验证，最终选定了TYROBP。TYROBP的高表达与ccRCC的低存活率相关，与免疫细胞浸润密切相关，并与程序性细胞死亡蛋白-1（PD-1 ）和细胞毒性T淋巴细胞相关抗原-4（CTLA-4）共表达。总之，TYROBP可能具有诊断和治疗 ccRCC 的潜力。

"点击查看英文标题和摘要"

TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) exhibits high recurrence and metastasis rates. Although target therapy has significantly improved the prognosis of some patients with ccRCC, the median survival rate remains poor. Thus, there remains a need for the identification of novel potential targets for diagnosis and therapy. Here, we screened differentially expressed genes between ccRCC and normal tissues through analyzing The Cancer Genome Atlas database. We identified 55 up‐regulated and 67 down‐regulated genes associated with poor prognosis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that these genes were associated with glycometabolic process, complement and coagulation cascades. In addition, the eight down‐regulated genes (HRG, FABP1, ALDOB, PCK1, HAO2, CASR, PLG, and HMGCS2) and two up‐regulated genes (SERPINE1 and TYROBP) were filtered out. Finally, TYROBP was selected through repeated verification of various databases. High expression of TYROBP is associated with low survival rate in ccRCC, is closely related to immune cell infiltration and is coexpressed with Programmed cell death protein‐1(PD‐1) and Cytotoxic T lymphocyte‐associated antigen‐4(CTLA‐4). In conclusion, TYROBP may have potential for diagnosis and treatment of ccRCC.

更新日期：2020-12-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南